Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

NCT03338114 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Amyotrophic Lateral Sclerosis
Fasciculation

Interventions

DRUG: FLX-787-ODT (orally disintigrating tablet)

Sponsor

Flex Pharma, Inc.